AstraZeneca PLC Director/PDMR Shareholding (1090G)
May 24 2017 - 10:00AM
UK Regulatory
TIDMAZN
RNS Number : 1090G
AstraZeneca PLC
24 May 2017
24 May 2017 15:00 BST
TRANSACTION BY PERSON DISCHARGING MANAGERIAL
RESPONSIBILITIES
Disclosure under Article 19 of the EU Market Abuse
Regulation
AstraZeneca PLC (the Company) announces that, on 23 May 2017, it
was notified by Mark Mallon, a Person Discharging Managerial
Responsibilities of the Company, that, on 23 May 2017, Mr Mallon
sold 20,000 American Depositary Shares (ADSs). Two ADSs are
equivalent to one ordinary share of $0.25 in the Company.
The attached notification, made in accordance with the
requirements of the EU Market Abuse Regulation, gives further
detail.
1 Details of the person discharging managerial
responsibilities / person closely associated
--- ---------------------------------------------------------------
a) Name Mark Mallon
--- ------------------------- ------------------------------------
2 Reason for the notification
--- ---------------------------------------------------------------
a) Position/status Person Discharging Managerial
Responsibilities
--- ------------------------- ------------------------------------
b) Initial notification Initial notification
/Amendment
--- ------------------------- ------------------------------------
3 Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
--- ---------------------------------------------------------------
a) Name AstraZeneca PLC
--- ------------------------- ------------------------------------
b) LEI PY6ZZQWO2IZFZC3IOL08
--- ------------------------- ------------------------------------
4 Details of the transaction(s): section to
be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transactions
have been conducted
--- ---------------------------------------------------------------
a) Description of AstraZeneca PLC American
the financial Depositary Shares
instrument, type
of instrument
CUSIP: 046353108
Identification
code
--- ------------------------- ------------------------------------
b) Nature of the Sale of AstraZeneca PLC American
transaction Depositary Shares
--- ------------------------- ------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
--------------- ----------
US$ 33.900214 20,000
--------------- ----------
--- ------------------------- ------------------------------------
d) Aggregated information Not applicable - single transaction
- Aggregated volume
- Price
--- ------------------------- ------------------------------------
e) Date of the transaction 23 May 2017
--- ------------------------- ------------------------------------
f) Place of the transaction NYSE
--- ------------------------- ------------------------------------
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company
that focuses on the discovery, development and commercialisation of
prescription medicines, primarily for the treatment of diseases in
three main therapy areas - Oncology, Cardiovascular & Metabolic
Diseases and Respiratory. The Company also is selectively active in
the areas of autoimmunity, neuroscience and infection. AstraZeneca
operates in over 100 countries and its innovative medicines are
used by millions of patients worldwide. For more information,
please visit www.astrazeneca.com and follow us on Twitter
@AstraZeneca.
Media Enquiries
Esra Erkal-Paler UK/Global +44 203 749 5638
Karen Birmingham UK/Global +44 203 749 5634
Rob Skelding UK/Global +44 203 749 5821
Jacob Lund Sweden +46 8 553 260 20
Michele Meixell US +1 302 885 2677
Investor Relations
Thomas Kudsk Larsen +44 203 749 5712
Craig Marks Finance, Fixed Income, M&A +44 7881 615 764
Henry Wheeler Oncology +44 203 749 5797
Mitchell Chan Oncology +1 240 477 3771
Lindsey Trickett Cardiovascular & Metabolic Diseases +1 240 543 7970
Nick Stone Respiratory +44 203 749 5716
Christer Gruvris Autoimmunity, Neuroscience & Infection +44 203 749 5711
US toll free +1 866 381 7277
Adrian Kemp
Company Secretary, AstraZeneca PLC
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHUSARRBVAVUAR
(END) Dow Jones Newswires
May 24, 2017 10:00 ET (14:00 GMT)
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024